Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions.

IF 7.6 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2025-07-30 DOI:10.1038/s41523-025-00800-4

Pooja Patel, Antonio Giordano, Sara Giordano, Ilana Schlam, Sara M Tolaney, Paolo Tarantino

引用次数: 0

Abstract

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads, leading to improved tumor delivery of the latter. After improving outcomes for patients with metastatic disease, ADC testing moved to the curative setting, where already one agent (trastuzumab emtansine) has been approved, after demonstrating to improve overall survival. Herein, we review the rationale, evidence, and challenges with the use of ADCs in the early-stage setting.

Abstract Image

查看原文本刊更多论文

治疗早期乳腺癌的抗体-药物结合物：目前的使用，预期的发展。

抗体-药物偶联物（adc）结合了单克隆抗体的特异性和有效的细胞毒性载荷，从而改善了后者的肿瘤递送。在改善转移性疾病患者的预后后，ADC测试转向治疗领域，已有一种药物（曲妥珠单抗emtansine）在证明可以改善总体生存后获得批准。在此，我们回顾了在早期环境中使用adc的基本原理、证据和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.